## Abstract ## BACKGROUND Adjuvant aromatase inhibitors (AIs), instead of or after tamoxifen, are effective in decreasing recurrence in postmenopausal women with estrogen receptor (ER)‐positive breast cancer. An understanding of which patients are at risk of early recurrence while they are receivi
Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen
✍ Scribed by Mahmoud R. Khoshnoud; Tommy Fornander; Hemming Johansson; Lars-Erik Rutqvist
- Publisher
- Springer US
- Year
- 2007
- Tongue
- English
- Weight
- 197 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio
## Abstract ## BACKGROUND. Results from numerous trials have indicated that breast‐conserving therapy (BCT) produces outcomes equivalent to those produced by mastectomy in terms of both locoregional control and survival. However, conservative treatment has resulted in the dilemma of how best to ad